ERLEC1: A Protein Targeted for Therapeutic Applications in Neurological Disorders

Target Name: ERLEC1

NCBI ID: G27248

ERLEC1

ERLEC1: A Protein Targeted for Therapeutic Applications in Neurological Disorders

ERLEC1 (CL25084) is a protein that is expressed in the brain and is known for its role in the regulation of neural circuits. Several studies have identified ERLEC1 as a potential drug target, with potential therapeutic applications in various neurological conditions, including Alzheimer's disease, Parkinson's disease, and schizophrenia.

The discovery of ERLEC1 as a potential drug target stems from a growing body of research that has shown the protein's involvement in the development and progression of neurological disorders. In particular, ERLEC1 has been shown to play a role in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

One of the key functions of ERLEC1 is its role in the regulation of the strengthening and plasticity of neural circuits. This protein is known to play a key role in the formation of synapses, which are the connections between neurons in the brain. By modulating the levels of other proteins involved in neural circuit development and function, ERLEC1 helps to regulate the growth and development of neural circuits.

In addition to its role in neural circuit regulation, ERLEC1 has also been shown to play a key role in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt in response to experience. This protein is known to play a key role in the formation of new synapses, as well as the strengthening of existing synapses.

The potential therapeutic applications of ERLEC1 as a drug target are vast. In addition to its potential role in the treatment of neurodegenerative diseases, ERLEC1 has also been shown to have potential applications in other neurological conditions, including mood disorders, anxiety disorders, and learning disorders.

For example, research has shown that ERLEC1 plays a key role in the regulation of emotional behavior in animals. In addition, studies have suggested that ERLEC1 may play a role in the development of symptoms of anxiety and depression.

In addition to its potential therapeutic applications, ERLEC1 has also been shown to be a promising biomarker for the diagnosis of neurological disorders. The levels of ERLEC1 have been shown to be altered in the brains of individuals with a variety of neurological disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia.

The identification of ERLEC1 as a potential drug target and biomarker has the potential to revolutionize our understanding of these neurological conditions and their treatments. Further research is needed to fully understand the role of ERLEC1 in neural circuit regulation and its potential therapeutic applications.

Protein Name: Endoplasmic Reticulum Lectin 1

Functions: Probable lectin that binds selectively to improperly folded lumenal proteins. May function in endoplasmic reticulum quality control and endoplasmic reticulum-associated degradation (ERAD) of both non-glycosylated proteins and glycoproteins

The "ERLEC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ERLEC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets